MoonLake Immunotherapeutics is exploding higher in sympathy with a broader biotech sector rally sparked by positive regulatory developments. Shares are moving in tandem with Biohaven Ltd, which surged 30.5% following the FDA's acceptance of its new drug application resubmission for Vyglxia. While there is no specific company-level news for MoonLake, the stock is benefiting from the positive sentiment surrounding the biotechnology industry as investors react to the latest FDA pipeline updates.